In TRAILBLAZER, Plasma GFAP Falls, but NfL Continues to Rise
While GFAP seems a sensitive biomarker of Aβ plaque removal, NfL might respond more slowly.
588 RESULTS
Sort By:
While GFAP seems a sensitive biomarker of Aβ plaque removal, NfL might respond more slowly.
Data from two large international familial cohorts predict disease onset, helping researchers select the best participants for secondary prevention trials.
Analysis of 168 metabolites in one blood sample foretold 10-year risk of developing common disorders.
VAMP2 helps distinguish pure dementia with Lewy bodies from DLB with Alzheimer’s. A synaptic protein panel distinguished FTLD-TDP-43 from FTLD-tau.
In this classification scheme, T, i.e. tau, means different things. Phospho-tau predicts tangle buildup, whereas tau-PET signals neurodegeneration and cognitive decline.
Soluble p-tau, aggregation epicenters, and gene variants emerged as potential forces that might influence how quickly tangles propagate through the brain.
In a large European study, the scans changed the diagnosis in a third of cases. They boosted the doctor's confidence in making the call, and predicted cognitive decline.
Plasma p-tau217 and p-tau181 better track amyloid PET, tangles, and subtle cognitive decline.
Certain blood biomarker tests can tell that amyloid has built up in a person's brain and that their thinking will decline. What are the challenges ahead before these tests can be rolled out to medical care settings everywhere?
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
Finally, blood biomarkers for AD are here. Alas, the path to routine use is fraught. At AAIC, scientists discussed new guidelines, head-to-head comparisons, and logistical, technical, and ethical hurdles ahead.
At AAIC, secondary endpoint data from the API Colombian study showed trends favoring crenezumab, while people taking gantenerumab in open-label extensions declined more slowly than matched controls.
In young adults with Down’s, plasma phospho-tau217 correlated with amyloid and tau PET positivity. With great accuracy.
At the Holloway Summit, scientists, regulatory, and foundation leaders discussed how to advance digital biomarkers from the idea stage into standardized, reliable tools for diagnosis and trials.
The inaugural Holloway Summit, hosted by AFTD, focused on the development of digital health technologies to track the progression of FTD’s myriad manifestations.